Siemens announces first U.S. deployment of new lab process control system
BIND Biosciences launches first implementation phase as it develops new nanoparticle drug delivery platforms. Goal is shorter time to market. Link to related resources.
Atlanta, GA – One of the drivers of the pharmaceutical industry is having an effective pipeline of new product developments. Since new products can be patented and sold on an exclusive basis, manufacturers want to shorten the time to market as much as regulations will permit. Siemens has created an extensionof its Simatic PCS 7 process control platform called PCS 7 Lab which is designed to help capture intellectual property developed in the lab so that it can be used again when a product is ready for scale-up with larger manufacturing batches.
Siemens announced that BIND Biosciences Inc., of Cambridge, MA, is the first user in the U.S. that has selected the PCS 7 Lab platform to help its scientists manage pre- and post-clinical experimental data.
BIND Biosciences develops targeted therapeutics based upon its novel polymeric nanoparticle drug delivery technology platform. The drug itself is encased in a nano-container that is designed to seek out and attach itself to specific types of cells, such as a tumor. That way the therapeutic agent can be delivered exactly where it is needed. This technology concentrates the drug at the intended site of action while minimizing systemic exposure, improving efficacy and reducing off-target effects.
“The flexibility and expandability of the PCS 7 Lab system will allow us to grow economically and efficiently through all three phases of the implementation,” says Jeff Hrkach, BIND Biosciences vice president of pharmaceutical sciences. “The system has all the tools we need to collect and manage our data as well as protect our intellectual property.”
The PCS 7 Lab configuration, designed for laboratory and process development research and development applications, is based on Siemens’ Simatic PCS 7 Box. The UL-certified system includes a preinstalled rack of I/O modules that can be easily reconfigured to fit any size or type of laboratory environment.
"This partnership gives Siemens the opportunity to help BIND bring drugs to market faster," says Glenn Restivo, Siemens life sciences industry manager. “We adhere to the design of experiment and quality by design philosophies that build quality into every step of the process– from laboratory experimentation through every phase of manufacturing.”
BIND’s implementation of the PCS 7 project is underway and focuses on basic experimentation and data collection. A second phase is under consideration for cataloging and organizing experimental data. Phase three, also under consideration, will include Siemens’ Sipat for process analytical technology (PAT), Interspec for specification management and the R&D Suite for electronic lab notebook (ELN).
- OPC Foundation releases draft ADI specification, aims to improve analyzer integration ; and
- A pproach for measuring economic benefit of process analytical technologies (PAT) .
Edited by Peter Welander, process industries editor
Control Engineering News Desk
Register here to select your choice of free eNewsletters .
- Events & Awards
- Magazine Archives
- Digital Reports
- Global SI Database
- Oil & Gas Engineering
- Survey Prize Winners